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Staging Metastasis Profile of Non-small Cell Lung Cancer:
A New Paradigm?
Jean Louis Pujol, MD, and Mohammad Chakra, MD
The 1997 edition of the Mountain stage grouping1 has been in its time a milestone in themodern management of non-small cell lung cancer (NSCLC). This TNM classification
has allowed research groups to perform cooperative studies in homogeneous patient
populations. Consequently, new therapeutic concepts have emerged for some subgroups
of patients by developing new treatment strategies, particularly combined modalities.
Nevertheless, after a decade of good and faithful services, there is an urgent need for
a revision of the TNM classification. Characteristics of the disease, progress in anticancer
therapy, and knowledge of the tumor biology have all evolved in the past decade. In the
present issue of the Journal of Thoracic Oncology,2 Postmus et al. build interesting
proposals based on a large population of patients (n  5592). A redefinition of the M
status of NSCLC patients would certainly help daily practice as well as further research.
The new International Association for the Study of Lung Cancer (IASLC) staging system
is eagerly awaited by both clinicians and researchers.
Based on a validated patient database, the authors made three important recommen-
dations that may be considered in the forthcoming 7th edition of the staging system:
1. Reclassify pleural dissemination (malignant pleural effusions, pleural nodules) from
T4 to M1a.
2. Subclassify M1 by additional nodules in the contralateral lung as M1a.
3. Subclassify M1 by distant metastases (outside the lung/pleura) as M1b.
Authors must be acknowledged for their efforts in proposing subclassifications. The
first proposal is logical as patients with malignant pleural effusion are eligible neither for
surgery nor radiotherapy. The other two are quite innovative and raise the important
question: is there a need for defining subclassification of metastatic profile? If yes, what
would be the best way to define groups with different prognosis requiring tailored
therapeutic strategies?
During the past two decades, the metastatic profile of NSCLC has changed
considerably. Three possible reasons might be highlighted: (1) the drastic increase in lung
adenocarcinoma in the spectrum of all histologies3 with a concomitant increase in the
frequency of NSCLC skipping nodal station towards hematogenous metastasis,4 (2) the
improvement of the metastases detecting methods,5 and (3) the emergence of efficient
multimodality therapy that can be proposed for patients with oligometastatic disease (e.g.,
solitary brain metastases6 or adrenal gland metastases7). Before commenting on the
current proposals from the IASLC Lung Cancer Staging Project, we briefly emphasize the
following points.
1. NSCLC is characterized by its tumor cell instability and the expression of cellular
diversification mechanisms. It has long been known that diversified malignant cells
differ by quantitative and few qualitative gene expressions, which may explain their
abilities to undergo rapid changes in phenotypic properties and progression to
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metastatic phenotype.8 The biological mechanisms un-
derlying both stromal and clonal expansion of NSCLC
are so complex that these disease features escape any
oversimplification in a clinical model of metastatic
disease.9,10 However, recent literature suggests that oli-
gometastatic disease is not uncommon and requires
specific management.
2. The workup of NSCLC has evolved during the past
decade. First, many institutions have adopted system-
atic brain magnetic resonance imaging at presentation,
taking into account the frequent occurrence of asymp-
tomatic brain metastases in nonsquamous histologies.4
Second, the PLUS multicenter trial has clearly demon-
strated that the addition of [18F]fluoro-2-deoxy-D-glu-
cose positron emission tomography (FDG-PET scan) to
the standard workup results in the frequent refinement
of lung cancer staging and avoids futile thoracotomies
in as many as 20% of patients otherwise considered as
eligible for surgery.11 Following this randomized trial,
other studies demonstrated that the combined use of
computed tomography and PET in dual imaging in-
creases the number of patients with correctly staged
NSCLC (for a review, see Vansteenkiste and Stroo-
bants5). FDG-PET also improves extrathoracic staging
through detection of lesions missed at conventional
imaging or characterization of lesions seen with con-
ventional imaging. However, the enthusiasm regarding
FDG-PET scan has been lowered by the observation
that false positives are not infrequent when one consid-
ered solitary nodules contralateral to the primary lung
cancer. Therefore, histologic characterization of con-
tralateral FDG-PET–positive nodules might be recom-
mended to not erroneously deny a patient surgery.
The study by Postmus et al. is based on a companion
paper12 proposing that the case of “satellite” nodules ipsilat-
eral to the primary lesion might be reconsidered: T3 if the
nodule is located in the same lobe where the primary tumor
has developed and T4 if the nodule is located in another lobe
ipsilateral to the primary lesion. This proposal seems logical.
In addition, it is in complete agreement with a recent article
published by the Journal of Thoracic Oncology reporting
analysis of 6525 patients who underwent a surgical resection
for NSCLC with intrapulmonary metastases.13 In this study,
no survival difference was detected when patients with a
satellite metastatic nodule in the same lobe as the primary
tumor were compared with patients with a satellite nodule in
a different lobe. The 1997 Mountain stage grouping, which
proposed considering disease with satellite nodule in another
lobe ipsilateral to the primary tumor such as M1 disease,
probably had overestimated the impact of this feature as a
negative prognostic determinant. This is now perfectly evi-
dent when looking at Figures 1 and 2 in the article by
Postmus et al. With these prognostic data in mind, the next
step would be to determine whether these patients with stage
T4 including same-side satellite nodules might be referred to
combined modality therapy including surgery and adjuvant
chemotherapy.
The subclassification of hematogenous metastases in
M1a and M1b, the latter characterized by distant metastases
outside the lung or the pleura yielding the worse prognosis
might be seriously considered.
There is no discussion that this subclassification has a
prognostic impact taking into account the survival effect of
this staging in the patient population or in the Surveillance
Epidemiology and End Results database. However, in the
past, there have been some attempts to identify different
subgroups of patients according to their metastatic profile that
might also be considered. The number of involved organs or
some specific sites (liver) are both considered as indicating a
very poor prognosis. On the contrary, patients with a solitary
metastasis with a surgically resectable primary tumor may
have a long-term survival pending adequate multimodality
treatment. Rubin et al.14 in a provocative paper suggested that
solitary metastases might be considered in a specific group
even if this is a rare clinical situation.
In the current IASLC Lung Cancer Staging Project
proposal, the subclassification of metastatic profile into M1a
and M1b is an interesting first step, which enables us to
clarify the management of NSCLC. However, there might be
in this study unexpected parameters partially explaining sur-
vival differences between the two groups. Some of solitary
nodules that have developed in the lung contralateral to the
primary site might be in fact a second cancer. This is
mentioned by the authors in the discussion when they state:
“Without comparing a tissue sample of both lesions, the
question usually remains unanswered, and even if identical
histology is found, this does not exclude two primary tu-
mors.” It is noteworthy that the reverse is also true as
phenotypic heterogeneity of lung cancer might explain dif-
ferences in histologic typing between the primary tumor and
the metastasis. Therefore, considering these patients as be-
longing to an M1a group could have been a bias improving
survival in this subpopulation. Conversely, the M1b group is
mainly described as a group of patients with evident meta-
static disease involving more than one organ in as many as
43%. Probably the M1b status for these patients was clini-
cally obvious as the histology of metastasis was demonstrated
in only 34 of 4350 patients. This presents a possible bias,
which makes the prognosis of this group worse.
In conclusion, we must thank the IASLC Lung Cancer
Staging Project for this important step toward a new and more
effective stage grouping. This important work opens a new field
investigation to propose adapted therapy to NSCLC patients.
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